Estrogen and cardiovascular disease.

Area of Science:

• Reproductive endocrinology and cardiovascular science.
• Investigates the role of sex hormones in cardiovascular health.

Background:

• Extensive research over 20 years highlights cardiovascular benefits of estradiol (E2) and progesterone (P4) in reproductive-aged women.
• Absence of ovarian E2 and P4 is associated with accelerated cardiovascular disease (CVD) development.
• Hormone replacement therapy (HRT) with E2 and P4 has demonstrated safety in younger menopausal women.

Purpose of the Study:

• To support reconsideration of E2 and P4 as preventative therapeutics for CVD reduction.
• To emphasize the importance of the 'Timing Hypothesis' for delaying CVD in postmenopausal women.

Main Methods:

• Review of accumulated scientific research over the past twenty years.
• Analysis of data regarding cardiovascular benefits and risks associated with E2 and P4.
• Consideration of the 'Timing Hypothesis' in the context of HRT initiation.

Main Results:

• Robust scientific data supports the cardiovascular benefits of E2 and P4.
• HRT with E2 and P4 has shown no harm in younger menopausal women.
• Expanded understanding of E2's modulatory role in CVD onset is crucial.

Conclusions:

• Reconsideration of prescriptive E2 and P4 use for CVD prevention is warranted, even without large-scale trials like WHI.
• Initiation of HRT shortly after ovarian function cessation ('Timing Hypothesis') should be considered to delay CVD in recently postmenopausal women.